🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522617-39-00
Completed Phase I

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia

2025-522617-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Verve Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
30/03/2026
Enrollment target
10
Sites
Netherlands

Condition studied

Refractory hyperlipidemia

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522617-39-00 on CTIS ↗ ← All trials in the EU